Navigation Links
Abbott's Humira(r) (Adalimumab) Gets Approval by EU for Crohn's Disease Treatment

ABBOTT PARK, Ill., Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA(R) (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease. This announcement follows FDA approval for the Crohn's disease indication, which Abbott received in February, and is the fourth approved indication for HUMIRA in the United States and the European Union.

Crohn's disease is a serious, chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than 1 million people in North America and Europe. It affects people of all ages, but it is primarily a disease of young adults, with onset typically before age 40. There is no medical or surgical cure for Crohn's disease and few treatment options exist for patients suffering with this chronic condition.

"Crohn's can have a devastating impact on patients, many of whom are young and active, making it difficult to carry out normal day-to-day activities," said Rod Mitchell, chairman, European Federation of Crohn's & Ulcerative Colitis Associations. "The unpredictable nature of the disease can seriously impact their quality of life and self-esteem. For the half million people across Europe suffering from Crohn's, this approval offers hope to help them regain control of their disease."

Common symptoms of Crohn's disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, fistulas (ulcers that form tunnels to surrounding tissues), and malnutrition. Over the course of their disease, as many as 75 percent of patients with Crohn's disease will undergo surgery at least once for complications or disease resistant to treatment. Of thos
'"/>




Page: 1 2

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
(Date:3/3/2015)... DePuy Pinnacle hip lawsuits (( ... the artificial hip system caused recipients to suffer ... in the federal multidistrict litigation underway in U.S. ... the most recent Master Case List issued by ... hip replacement lawsuits are now pending in the ...
(Date:3/3/2015)... With a grant of more than $4.5 ... has been named a national coordinating center by the ... for Health: Improving Community Health Through Innovations in Financing ... health and reduce disparities through innovations in collaboration and ... of the center and up to 10 communities over ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Dallas ... as chairman of the upcoming Dallas Rhinoplasty Symposium, to ... three day symposium, which is attended by plastic surgeons ... provide surgeons with detailed information on current topics, emerging ... revision rhinoplasty surgery . , The symposium will ...
(Date:3/3/2015)... March 03, 2015 Retrofit , ... at America’s leading corporations, today announces the appointment of ... executive positions. CEO Mary Pigatti has recruited ... and employee engagement for the fast-growing company, which was ... watch for 2015. , “Retrofit is thrilled to ...
(Date:3/3/2015)... Celestix Networks, the leading provider ... the global availability of Celestix Cloud Edge Security ... most deployed platform for DirectAccess and remote access ... new release enables organizations to manage the Windows® ... single HTML 5 web interface called Comet 2.0. ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4Health News:Robert Wood Johnson Foundation Names Georgia Health Policy Center National Center for Bridging for Health Initiative 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 2Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 3
... medicine is world renowned. It has supernatural effects on ... such article was recently reported in the November 7 ... the great significance of a Chinese medicinal compound, delisheng, ... method. The research team was led by Dr. Ke-Jun ...
... ID at-risk patients years before clinical diagnosis, scientists say ... An international team of scientists has developed a blood ... impairment will go on to develop Alzheimer,s disease. , ... of effective treatments against Alzheimer,s in the future -- ...
... October 15, 2007 New research presented at ... College of Gastroenterology emphasizes the importance of colorectal ... who have a higher incidence of colorectal cancer ... African-Americans had advanced polyps on the right side ...
... 2007 Post-hoc and other analyses of secondary endpoints ... plc,s (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis ... in patients with mild to moderate ulcerative colitis. These ... open-label 12-14 month extension study, are being presented this ...
... Level I and II,Trauma Center accreditation status has been ... 2007 through,September 30, 2008: Regional Resource Trauma Center (Level ... Johnstown -- Conemaugh Memorial Medical Center ... Philadelphia -- Hahnemann University Hospital ...
... TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals ... of cancer therapies, today announced that it held ... Drug Administration (FDA) at,which the FDA concurred with ... its lead drug, Neuradiab, a treatment for newly ...
Cached Medicine News:Health News:A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma 2Health News:Blood Test Might Spot Alzheimer's Early 2Health News:Blood Test Might Spot Alzheimer's Early 3Health News:Racial and ethnic differences in colorectal cancer emphasize importance of screening 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 4Health News:Pennsylvania Trauma Center Accreditation Status 2Health News:Bradmer provides Phase III Neuradiab trial update and guidance 2Health News:Bradmer provides Phase III Neuradiab trial update and guidance 3
(Date:3/3/2015)... -- This industry report package offers the most up-to-date market data on the ... world and in the top 10 global countries. Along with a global ... countries: Australia , China ... Italy , Japan , Russia ... , United States The reports include ...
(Date:3/3/2015)... , March 3, 2015 /CNW/ - The ... seized a health product being injected at Art Nails Ltd., located ... appeared to be unauthorized as it contained no labelling. All products ... authorized by Health Canada and must have approved labelling. ... had been administered to consumers. Potential risks associated with injecting an ...
(Date:3/3/2015)... , March 3, 2015 ... 356 and 240 patients respectively Publications in ... Journal of Clinical Gastroenterology highlight diagnostic value of ... China and across ... Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the ...
Breaking Medicine Technology:Global Safety Glass Market to 2019 - Market Size, Top 10 Countries, Trends, and Forecasts 2Advisory - Health product seized from Art Nails in Vancouver 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
... The e.cam single-detector system offers ... unrestricted access for gurneys and ... a clinically versatile open gantry, ... body contouring for SPECT and ...
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM...
Spring Type with lock. Titanium....
The REVEALRT and REVEALXVI PET/CT scanners combine our fastest PET scanner, the REVEALXL, with multi-slice spiral CT scanners from Siemens Medical Systems....
Medicine Products: